Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Treasury Shares (2016 - 2026)

Cryo Cell International's Treasury Shares history spans 17 years, with the latest figure at $25.0 million for Q1 2026.

  • Quarterly results put Treasury Shares at $25.0 million for Q1 2026, up 0.68% from a year ago — trailing twelve months through Feb 2026 was $25.0 million (up 0.68% YoY), and the annual figure for FY2025 was $25.0 million, up 0.68%.
  • Treasury Shares for Q1 2026 was $6.8 million at Cryo Cell International, roughly flat from $6.8 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $6.8 million in Q3 2025 to a low of $31808.0 in Q1 2024.
  • The 5-year median for Treasury Shares is $223999.0 (2024), against an average of $3.0 million.
  • The sharpest move saw Treasury Shares rose 9.44% in 2022, then grew 0.42% in 2025.
  • Year by year, Treasury Shares stood at $22.6 million in 2022, then grew by 3.53% to $23.4 million in 2023, then increased by 6.08% to $24.9 million in 2024, then rose by 0.68% to $25.0 million in 2025, then changed by 0.0% to $25.0 million in 2026.
  • According to Business Quant data, Treasury Shares over the past three periods came in at $25.0 million, $25.0 million, and $25.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.